People · Operator
Named in public records as an officer, director or promoter · active 2010–2025 · Pharmaceuticals, Other Health Care, Biotechnology, Robotics
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Enlaza Therapeutics, Inc. | — | Pharmaceuticals | Series C | $134.6M | $87.6M | 2021 |
| AristaMD, Inc. | — | Other Health Care | Series B | $71.2M | $136.4M | 2014 |
| Aratana Therapeutics, Inc. | — | Pharmaceuticals | Series B | $67.3M | $1.0B | 2010 |
| Otonomy, Inc. | — | Biotechnology | Series B | $44.8M | $961.1M | 2010 |
| Synthorx, Inc. | — | Biotechnology | Series B | $34.7M | $1.1B | 2014 |
| Carbon Robotics Inc. | — | Robotics | Seed | $5.5M | $86.0M | 2014 |
| Cellular Approaches, Inc. | — | Biotechnology | Seed | $2.6M | $113.7M | 2016 |
Jay Lichter at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jay Lichter on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Tighe Reardon | 4 | 7 |
| Douglas Downs | 4 | 6 |
| Court Turner | 3 | 6 |
| Jay Lichter, Ph.D. | 2 | 5 |
| ANDREW LEVIN | 1 | 17 |
| Peter Thompson | 1 | 16 |
| James Topper | 1 | 12 |
| David Rosen | 1 | 10 |
| Brant Heise | 1 | 10 |
| Shelley Chu | 1 | 10 |
| Jeffrey Harris | 1 | 9 |
| Peter Bisgaard | 1 | 9 |
| Stephen Squinto | 1 | 8 |
| David Weber | 1 | 8 |
| Brian Dovey | 1 | 7 |
| Thomas Cooper | 1 | 6 |
| John McKearn | 1 | 6 |
| John Kuelper | 1 | 6 |
| Heather Preston | 1 | 6 |
| Laura Shawver | 1 | 6 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.